What does this research mean for the field?

Heart failure with preserved ejection fraction is a complex, heterogeneous syndrome where phenotype-based classification and comprehensive management of comorbidities, alongside targeted therapies like SGLT2 inhibitors, offer a more effective approach than traditional LVEF-based categorization. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The aim is to address the complexities in diagnosing and managing heart failure with preserved ejection fraction (HFpEF).

January 12, 2022HeartOpen Access

Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management

View Full Paper

Ask AI

Bookmark

Why the study?

Heart failure with preserved ejection fraction accounts for approximately half of all heart failure cases but remains a diagnostic and therapeutic challenge.

Key Points

The aim is to address the complexities in diagnosing and managing heart failure with preserved ejection fraction (HFpEF).
Narrative review of recent literature on HFpEF diagnosis, pathophysiology, and treatment strategies.
Discusses advanced diagnostic methods like exercise echocardiography and invasive hemodynamics.
Explores comprehensive management approaches including addressing comorbidities and exercise.
Advanced diagnostic techniques are necessary to differentiate HFpEF from other dyspnea causes.
Sodium-glucose cotransporter 2 inhibitors significantly reduce HF hospitalizations in HFpEF.
Targeting treatment based on phenotypes may improve patient outcomes compared to relying solely on LVEF.

Structured PICO

Population

Patients with heart failure with preserved ejection fraction (HFpEF)

This narrative review summarizes the pathophysiology, diagnosis, classification, and management of patients with HFpEF, highlighting the shift towards phenotype-based classification and the role of SGLT2 inhibitors.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

May support SGLT2 inhibitor preference in HFpEF; leaves open phenotype-specific trials versus RAAS/ARNI.

Cite This Study

Gevaert et al. (2022) studied this question.

synapsesocial.com/papers/6a1d27e934b1fc2f2476e7bc https://doi.org/10.1136/heartjnl-2021-319605

Topics

HFrEF treatment Heart failure HFpEF management Heart failure hospitalization

View Full Paper

Ask AI

Bookmark

Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Topics

Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider